JP2025501141A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP2025501141A
JP2025501141A JP2024538669A JP2024538669A JP2025501141A JP 2025501141 A JP2025501141 A JP 2025501141A JP 2024538669 A JP2024538669 A JP 2024538669A JP 2024538669 A JP2024538669 A JP 2024538669A JP 2025501141 A JP2025501141 A JP 2025501141A
Authority
JP
Japan
Prior art keywords
cycloalkyl
heterocycloalkyl
alkyl
haloalkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501141A5 (enExample
Inventor
バニスター サミュエル
ジョージェンセン ウィリアム
ジンロン タン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psylo Pty Ltd
Original Assignee
Psylo Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904268A external-priority patent/AU2021904268A0/en
Application filed by Psylo Pty Ltd filed Critical Psylo Pty Ltd
Publication of JP2025501141A publication Critical patent/JP2025501141A/ja
Publication of JP2025501141A5 publication Critical patent/JP2025501141A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024538669A 2021-12-24 2022-12-23 化合物 Pending JP2025501141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904268 2021-12-24
AU2021904268A AU2021904268A0 (en) 2021-12-24 Compounds
PCT/AU2022/051591 WO2023115165A1 (en) 2021-12-24 2022-12-23 Compounds

Publications (2)

Publication Number Publication Date
JP2025501141A true JP2025501141A (ja) 2025-01-17
JP2025501141A5 JP2025501141A5 (enExample) 2026-01-08

Family

ID=86900872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538669A Pending JP2025501141A (ja) 2021-12-24 2022-12-23 化合物

Country Status (10)

Country Link
US (1) US20250163044A1 (enExample)
EP (1) EP4452979A4 (enExample)
JP (1) JP2025501141A (enExample)
KR (1) KR20240128059A (enExample)
CN (1) CN118974044A (enExample)
AU (1) AU2022422215A1 (enExample)
CA (1) CA3241845A1 (enExample)
IL (1) IL313857A (enExample)
MX (1) MX2024007911A (enExample)
WO (1) WO2023115165A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
JP2026524104A (ja) * 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
WO2026030052A1 (en) 2024-07-31 2026-02-05 Fmc Corporation Fungicidal substituted azoles
WO2026137050A1 (en) * 2024-12-24 2026-07-02 Psylo Pty Ltd Compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
GB9819020D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
EP1132389A1 (en) * 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
EP1513521A2 (en) * 2002-05-30 2005-03-16 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US7964728B2 (en) * 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
ES2374581T3 (es) 2006-07-06 2012-02-20 Abbott Healthcare Products B.V. Derivados de azaindol con una combinación de agonismo parcial del receptor nicotínico de la acetilcolina e inhibición de la reabsorción de dopamina.
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
US9073851B2 (en) * 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole
CA3182093A1 (en) * 2020-06-10 2021-12-16 Florence Wagner Tricyclic psychoplastogens and uses thereof
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same

Also Published As

Publication number Publication date
AU2022422215A1 (en) 2024-08-01
CA3241845A1 (en) 2023-06-29
WO2023115165A1 (en) 2023-06-29
KR20240128059A (ko) 2024-08-23
US20250163044A1 (en) 2025-05-22
CN118974044A (zh) 2024-11-15
EP4452979A1 (en) 2024-10-30
MX2024007911A (es) 2024-09-10
IL313857A (en) 2024-08-01
EP4452979A4 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
US20250163044A1 (en) Compounds
US20250101038A1 (en) Compounds
US12415804B2 (en) Compounds for activating a serotonin receptor
CN117337289A (zh) 用于治疗脑病症的四环化合物
CN116472274A (zh) 氮杂环丁烷基色胺和治疗精神障碍的方法
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
US20250333371A1 (en) Compounds
US12428380B2 (en) Compounds
WO2025118034A1 (en) Compounds active at the serotonergic 5-ht2a receptor
WO2025104491A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251223